Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROCSTAR study of oral ROC-101 in PAH and ILD-associated pulmonary hypertension
2025-522074-37-00Phase 2Authorised
- Sponsor
- AllRock Bio
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of ROC-101 in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), sponsored by AllRock Bio. Primary endpoints: Change in pulmonary vascular resistance and Safety and tolerability. Planned start Dec 2025; status: authorised.
02
Drugs
ROC-101
03
Conditions
pulmonary arterial hypertension (PAH)pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Beyond the preview
Go deeper on 2025-522074-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522074-37-00.